{"id":"nucleoside-analogue-sparing-haart-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Lipid elevation (cholesterol, triglycerides)"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Rash (NNRTI-related)"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen strategy avoids nucleoside analogues (NRTIs) such as AZT, which are associated with mitochondrial toxicity, lipodystrophy, and metabolic complications. Instead, it relies on alternative drug classes—typically a ritonavir-boosted protease inhibitor combined with a non-nucleoside reverse transcriptase inhibitor (NNRTI)—to achieve viral suppression while reducing long-term toxicity burden.","oneSentence":"A nucleoside analogue-sparing antiretroviral regimen uses protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors to suppress HIV replication without the toxicity associated with nucleoside reverse transcriptase inhibitors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:55.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment-naive or treatment-experienced patients)"}]},"trialDetails":[{"nctId":"NCT00135460","phase":"PHASE4","title":"Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients","status":"UNKNOWN","sponsor":"Danish HIV Research Group","startDate":"2003-06","conditions":"HIV-Associated Lipodystrophy Syndrome","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"nucleoside analogue sparing HAART regimen","genericName":"nucleoside analogue sparing HAART regimen","companyName":"Danish HIV Research Group","companyId":"danish-hiv-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A nucleoside analogue-sparing antiretroviral regimen uses protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors to suppress HIV replication without the toxicity associated with nucleoside reverse transcriptase inhibitors. Used for HIV-1 infection (treatment-naive or treatment-experienced patients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}